In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)

Not Applicable

Completed

• Conditions: Polycystic Ovarian Syndrome
• Interventions: Other: IVM

• Registration Number: NCT01237106
• Lead Sponsor: University Reproductive Associates

Brief Summary

This pilot study will be a prospective investigation to study the efficacy and safety of In-Vitro Maturation (IVM) for women with Polycystic Ovarian Syndrome (PCOS). There will be 10 subjects total in this Study. There will be no blinding to treatment.

In-Vitro Maturation will provide a viable, safe option for women with PCOS attempting pregnancy through the use of Assisted Reproductive Technology (ART).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-03
• Study First Submitted QC: 2010-11-08
• Study First Posted: 2010-11-09
• Primary Completion: 2012-02
• Study Completion: 2012-11
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-01
• Last Update Posted: 2015-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
In Vitro Maturation (IVM)	IVM	-

Primary Outcome Measures

Name	Time	Method
Incidence of Biochemical Pregnancy (defined as a rising Beta-HCG level).	6 months

Secondary Outcome Measures

Name	Time	Method
rates of maturation and fertilization	6 months
Incidence of Ovarian Hyperstimulation Syndrome (OHSS)	6 months
live births	1 1/2 years
number of immature oocytes retrieved	6 months

Trial Locations

Locations (1)

University Reproductive Associates; 🇺🇸 Hoboken, New Jersey, United States